首页> 外文期刊>Chinese Medical Journal >Diffuse panbronchiolitis complicated with thymoma: a report of 2 cases with literature review
【24h】

Diffuse panbronchiolitis complicated with thymoma: a report of 2 cases with literature review

机译:弥漫性全细支气管炎并发胸腺瘤2例报道并文献复习

获取原文
获取原文并翻译 | 示例
       

摘要

Objective Diffuse panbronchiolitis, a distinct clinical entity of unknown etiology, has been reported originally and primarily in Japanese and rarely in non-Japanese populations. Macrolide therapy is effective for this once dismal disease. Diffuse panbronchiolitis complicated with thymoma is uncommon; only 2 cases have been reported to date. The aims of this study were to describe the clinical profiles, assess the response to macrolide therapy, and to discuss the possible pathogenesis of diffuse panbronchiolitis in this setting. Methods The clinical profiles, macrolide therapy response of diffuse panbronchiolitis complicated with encapsulated thymoma in 2 histologically confirmed cases were described and discussed with the 2 cases reported in the literature: one complicated with encapsulated thymoma, another with invasive thymoma. Results Of the 2 cases, both had negative PPD skin testing and abnormal serum levels of various immunoglobulins, 1 had positive anti-nuclear antibody, but none had elevated cold hemagglutinin titers, and both had an excellent response to macrolide therapy. Of the 2 cases reported in the literature, both had negative PPD or tuberculin skin testing, 1 had severe hypogammaglobulinemia, 1 had elevated IgA, 1 had positive anti-DNA, 1 had elevated cold hemagglutinin titers, but both died of respiratory failure in spite of macrolide therapy in 1 case. Conclusions Prognosis for diffuse panbronchiolitis complicated with thymoma may depend on the nature of the thymoma and on the disease course. Macrolide therapy is also effective if administered early in the disease course and if the thymoma is cured. Immunological factors may play an important role in the pathogenesis of diffuse panbronchiolitis in this setting.
机译:目的弥漫性全细支气管炎是一种病因不明的独特临床实体,最初在日本报道,主要在日本人中报道,很少在非日本人中报道。大环内酯类疗法对于这种曾经令人沮丧的疾病是有效的。弥漫性全细支气管炎并发胸腺瘤并不常见。迄今为止,仅报道了2例。这项研究的目的是描述临床情况,评估对大环内酯类药物治疗的反应,并讨论在这种情况下弥漫性全细支气管炎的可能发病机制。方法对2例经组织学证实的弥漫性全细支气管炎并发封装性胸腺瘤的临床资料,大环内酯类药物的治疗反应进行描述,并与文献报道的2例病例进行讨论:1例并发封装性胸腺瘤,另一例合并浸润性胸腺瘤。结果2例患者的PPD皮肤测试均为阴性,各种免疫球蛋白的血清水平异常,其中1例抗核抗体阳性,但无冷血凝素滴度升高,且均对大环内酯类药物有良好的反应。在文献报道的2例中,PPD或结核菌素皮肤试验均为阴性,1例严重低水平球蛋白血症,1例IgA升高,1例抗DNA阳性,1例冷血凝素滴度升高,但均因呼吸衰竭而死亡大环内酯治疗1例。结论弥漫性全细支气管炎合并胸腺瘤的预后可能取决于胸腺瘤的性质和病程。如果在疾病过程的早期以及胸腺瘤治愈后,大环内酯疗法也有效。在这种情况下,免疫因素可能在弥漫性全细支气管炎的发病机理中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号